GHK-Cu

Quote
RESEARCH USE ONLY COA AVAILABLE

Copper tripeptide researched for tissue repair and skin health.

Net quantity
Format
Lyophilized
Storage
≤25°C · dark
Example lot
24-1187
Catalog no.
CRL-WEL-GHKCU-100
Retest
MFG + 24 mo
Not for human or veterinary use, nor for use in diagnostics or therapeutics. Catalog entries describe material and documentation only.
Research dossier

GHK-Cu

Compound monograph CRL-WEL-GHKCU-100
01

Background

GHK-Cu is a copper-binding tripeptide (glycyl-L-histidyl-L-lysine) complexed with copper(II), first isolated from human plasma. It has been studied for roles in tissue remodeling, collagen and glycosaminoglycan synthesis, antioxidant activity, and modulation of gene expression related to wound repair.

The copper peptide is well characterized in dermatological and wound-healing research and is widely used in cosmetic formulation, with a substantial in-vitro and animal literature.

02

Selected literature

  1. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences. 2018;19(7):1987.
  2. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International. 2015;2015:648108.
  3. Pickart L. The human tripeptide GHK and tissue remodeling. Journal of Biomaterials Science. 2008;19(8):969-988.

References are provided for scientific context only. Citation does not imply endorsement of any use, nor a claim of safety or efficacy. Findings frequently derive from in-vitro or animal models.

03

Trademarks & attribution

The GHK-Cu tripeptide was first described by Loren Pickart. It appears in cosmetic products under various proprietary names owned by their respective manufacturers; the compound itself is not trademark-restricted. Supplied as reference material only.

Age Verification

You must be at least 21 years of age to enter this site. By entering, you agree to our terms of service and research-only policy.